75 related articles for article (PubMed ID: 16750022)
1. [Randomized phase II trial on escalated doses of Rh-endostatin (YH-16) for advanced non-small cell lung cancer].
Yang L; Wang JW; Sun Y; Zhu YZ; Liu XQ; Li WL; Di LJ; Li PW; Wang YL; Song SP; Yao C; You LF
Zhonghua Zhong Liu Za Zhi; 2006 Feb; 28(2):138-41. PubMed ID: 16750022
[TBL] [Abstract][Full Text] [Related]
2. Phase II study of plitidepsin in pretreated patients with locally advanced or metastatic non-small cell lung cancer.
Peschel C; Hartmann JT; Schmittel A; Bokemeyer C; Schneller F; Keilholz U; Buchheidt D; Millan S; Izquierdo MA; Hofheinz RD
Lung Cancer; 2008 Jun; 60(3):374-80. PubMed ID: 18054408
[TBL] [Abstract][Full Text] [Related]
3. Cisplatin plus weekly vinorelbine versus cisplatin plus vinorelbine on days 1 and 8 in advanced non-small cell lung cancer: a prospective randomized phase III trial of the G.O.I.M. (Gruppo Oncologico Italia Meridionale).
Gebbia V; Galetta D; Lorusso V; Caruso M; Verderame F; Pezzella G; Borsellino N; Durini E; Valenza R; Agostara B; Colucci G;
Lung Cancer; 2008 Sep; 61(3):369-77. PubMed ID: 18308419
[TBL] [Abstract][Full Text] [Related]
4. [Results of randomized, multicenter, double-blind phase III trial of rh-endostatin (YH-16) in treatment of advanced non-small cell lung cancer patients].
Wang J; Sun Y; Liu Y; Yu Q; Zhang Y; Li K; Zhu Y; Zhou Q; Hou M; Guan Z; Li W; Zhuang W; Wang D; Liang H; Qin F; Lu H; Liu X; Sun H; Zhang Y; Wang J; Luo S; Yang R; Tu Y; Wang X; Song S; Zhou J; You L; Wang J; Yao C
Zhongguo Fei Ai Za Zhi; 2005 Aug; 8(4):283-90. PubMed ID: 21108883
[TBL] [Abstract][Full Text] [Related]
5. A phase I/randomized phase II, non-comparative, multicenter, open label trial of CP-547,632 in combination with paclitaxel and carboplatin or paclitaxel and carboplatin alone as first-line treatment for advanced non-small cell lung cancer (NSCLC).
Cohen RB; Langer CJ; Simon GR; Eisenberg PD; Hainsworth JD; Madajewicz S; Cosgriff TM; Pierce K; Xu H; Liau K; Healey D
Cancer Chemother Pharmacol; 2007 Jun; 60(1):81-9. PubMed ID: 17031646
[TBL] [Abstract][Full Text] [Related]
6. Phase III randomized, double-blind study of maintenance CAI or placebo in patients with advanced non-small cell lung cancer (NSCLC) after completion of initial therapy (NCCTG 97-24-51).
Johnson EA; Marks RS; Mandrekar SJ; Hillman SL; Hauge MD; Bauman MD; Wos EJ; Moore DF; Kugler JW; Windschitl HE; Graham DL; Bernath AM; Fitch TR; Soori GS; Jett JR; Adjei AA; Perez EA
Lung Cancer; 2008 May; 60(2):200-7. PubMed ID: 18045731
[TBL] [Abstract][Full Text] [Related]
7. Efficacy and safety of axitinib in patients with advanced non-small-cell lung cancer: results from a phase II study.
Schiller JH; Larson T; Ou SH; Limentani S; Sandler A; Vokes E; Kim S; Liau K; Bycott P; Olszanski AJ; von Pawel J
J Clin Oncol; 2009 Aug; 27(23):3836-41. PubMed ID: 19597027
[TBL] [Abstract][Full Text] [Related]
8. Phase I/II trial of weekly intravenous 130-nm albumin-bound paclitaxel as initial chemotherapy in patients with stage IV non-small-cell lung cancer.
Rizvi NA; Riely GJ; Azzoli CG; Miller VA; Ng KK; Fiore J; Chia G; Brower M; Heelan R; Hawkins MJ; Kris MG
J Clin Oncol; 2008 Feb; 26(4):639-43. PubMed ID: 18235124
[TBL] [Abstract][Full Text] [Related]
9. Do the time to chemotherapy response and the dose intensity have an impact on patient outcome in advanced non-small cell lung cancer?
Radosavljevic D; Golubicic I; Gavrilovic D; Kezic I; Jelic S
J BUON; 2009; 14(2):203-9. PubMed ID: 19650167
[TBL] [Abstract][Full Text] [Related]
10. Phase II, multicenter, uncontrolled trial of single-agent sorafenib in patients with relapsed or refractory, advanced non-small-cell lung cancer.
Blumenschein GR; Gatzemeier U; Fossella F; Stewart DJ; Cupit L; Cihon F; O'Leary J; Reck M
J Clin Oncol; 2009 Sep; 27(26):4274-80. PubMed ID: 19652055
[TBL] [Abstract][Full Text] [Related]
11. Induction chemotherapy with the TIP regimen (paclitaxel/ifosfamide/cisplatin) in stage III non-small cell lung cancer.
Pohl G; Krajnik G; Malayeri R; Müller RM; Klepetko W; Eckersberger F; Schäfer-Prokop C; Pokrajac B; Schmeikal S; Maier A; Ambrosch G; Woltsche M; Minar W; Pirker R
Lung Cancer; 2006 Oct; 54(1):63-7. PubMed ID: 16926060
[TBL] [Abstract][Full Text] [Related]
12. Randomized, phase III study of weekly paclitaxel in combination with carboplatin versus standard every-3-weeks administration of carboplatin and paclitaxel for patients with previously untreated advanced non-small-cell lung cancer.
Belani CP; Ramalingam S; Perry MC; LaRocca RV; Rinaldi D; Gable PS; Tester WJ
J Clin Oncol; 2008 Jan; 26(3):468-73. PubMed ID: 18202422
[TBL] [Abstract][Full Text] [Related]
13. [Assessment of the cardiotoxicity of recombinant human endostatin using myocardial biochemical markers in cancer patients].
Qin J; Zhang PH; Qian XY; Kang SJ; Luo RC; Wang YG
Nan Fang Yi Ke Da Xue Xue Bao; 2008 Jun; 28(6):930-2. PubMed ID: 18583230
[TBL] [Abstract][Full Text] [Related]
14. Phase 2 study of mapatumumab, a fully human agonistic monoclonal antibody which targets and activates the TRAIL receptor-1, in patients with advanced non-small cell lung cancer.
Greco FA; Bonomi P; Crawford J; Kelly K; Oh Y; Halpern W; Lo L; Gallant G; Klein J
Lung Cancer; 2008 Jul; 61(1):82-90. PubMed ID: 18255187
[TBL] [Abstract][Full Text] [Related]
15. Phase II clinical trial of the epothilone B analog, ixabepilone, in patients with non small-cell lung cancer whose tumors have failed first-line platinum-based chemotherapy.
Vansteenkiste J; Lara PN; Le Chevalier T; Breton JL; Bonomi P; Sandler AB; Socinski MA; Delbaldo C; McHenry B; Lebwohl D; Peck R; Edelman MJ
J Clin Oncol; 2007 Aug; 25(23):3448-55. PubMed ID: 17606973
[TBL] [Abstract][Full Text] [Related]
16. Randomized phase III trial comparing bexarotene (L1069-49)/cisplatin/vinorelbine with cisplatin/vinorelbine in chemotherapy-naive patients with advanced or metastatic non-small-cell lung cancer: SPIRIT I.
Ramlau R; Zatloukal P; Jassem J; Schwarzenberger P; Orlov SV; Gottfried M; Pereira JR; Temperley G; Negro-Vilar R; Rahal S; Zhang JK; Negro-Vilar A; Dziewanowska ZE
J Clin Oncol; 2008 Apr; 26(11):1886-92. PubMed ID: 18398154
[TBL] [Abstract][Full Text] [Related]
17. Induction chemotherapy with paclitaxel plus carboplatin followed by paclitaxel with concurrent radiotherapy in stage IIIB non-small-cell lung cancer (NSCLC) patients: a phase II trial.
Pallarés C; Capdevila J; Paredes A; Farré N; Ciria JP; Membrive I; Basterrechea L; Gomez-Segura G; Barnadas A
Lung Cancer; 2007 Nov; 58(2):238-45. PubMed ID: 17658655
[TBL] [Abstract][Full Text] [Related]
18. Serum endostatin levels in patients with lung carcinoma.
Swidzińska E; Ossolińska M; Naumnik W; Trojan S; Chyczewska E
Rocz Akad Med Bialymst; 2005; 50():197-200. PubMed ID: 16358965
[TBL] [Abstract][Full Text] [Related]
19. Randomized phase II trial of OK-432 in patients with malignant pleural effusion due to non-small cell lung cancer.
Kasahara K; Shibata K; Shintani H; Iwasa K; Sone T; Kimura H; Nobata K; Hirose T; Yoshimi Y; Katayama N; Ishiura Y; Kita T; Nishi K; Nakatsumi Y; Ryoma Y; Fujimura M; Nakao S
Anticancer Res; 2006; 26(2B):1495-9. PubMed ID: 16619563
[TBL] [Abstract][Full Text] [Related]
20. Real-world outcomes of various regimens of recombinant human endostatin combined with chemotherapy in non-driver gene mutation advanced non-small cell lung cancer.
Wang Z; Zhang H; Zhou C; Long X; Guan R; Yang N; Zhang Y
Cancer Med; 2019 Apr; 8(4):1434-1441. PubMed ID: 30762300
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]